Johnson & Johnson (NYSE:JNJ) has presented Phase 1 clinical trial results for JNJ-6143, an investigational oral treatment for ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no ...

Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

Experimental oral drug JNJ-6143 produced strong PSA and tumor responses in patients with heavily treated advanced prostate ...

Among patients with metastatic or very high-risk nonmetastatic prostate cancer, lower prostate-specific antigen (PSA) levels during hormone-based therapy — particularly ≤ 0.2 ng/mL — were strongly ...

Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated ...

Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely ...

Salvage radiation after surgery: If PSA rises after surgery, radiation to the area where the prostate was can still be ...

Add Yahoo as a preferred source to see more of our stories on Google. b' Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023 ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.